relif-shutterstock-com
relif / Shutterstock.com
25 February 2016Americas

PTAB accepts Bass’s toenail patent challenges

The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board (PTAB) gave the go-ahead to two inter partes review petitions.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
Big Pharma
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.

More on this story

Americas
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
Big Pharma
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.

More on this story

Americas
24 February 2016   Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.
Big Pharma
17 November 2015   Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents from Kyle Bass’s organisation the Coalition for Affordable Drugs.